ESR1 and breast cancer: However, tumors in patients without ER, PR, and HER2 expression, commonly referred to triple‐negative breast cancer (TNBC), exhibit higher aggressiveness and metastatic potential compared to other BC subtypes (Ensenyat‐Mendez et al., 2021).